home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410m.zip
/
M94A2385.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
35 lines
Document 2385
DOCN M94A2385
TI Seroconversion to dual reactivity among HIV-1 and HIV-2 seropositive
women in Abidjan, Cote d'Ivoire.
DT 9412
AU Wiktor SZ; Ekpini E; Sibailly T; Diaby L; Teurquetil MJ; Tossou O;
DeCock KM; Greenberg AE; Projet RETRO-CI, Abidjan, Cote d'Ivoire.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):316 (abstract no. PC0195). Unique
Identifier : AIDSLINE ICA10/94370190
AB OBJECTIVE: To assess the rate of seroconversion from HIV-negative
(HIV-N) to HIV-1 or HIV-2 seropositivity and from HIV-1 or HIV-2
seropositivity to dual reactivity (HIV-D) in a cohort of women enrolled
in a study of perinatal HIV transmission in Abidjan, Cote d'Ivoire.
METHODS: From September 1990 to August 1992, HIV-1, HIV-2, and HIV-N
women were enrolled at delivery and followed until January 1994.
Six-monthly blood samples were screened for HIV antibodies by EIA and
confirmed by a synthetic peptide-based test (Peptilav) or Western blot.
HIV serotype (HIV-1, HIV-2, or HIV-D) was determined by Peptilav, and
seroconversion (SC) was defined as a change in Peptilav result.
Lymphocyte subtyping was performed. TABULAR DATA, SEE ABSTRACT VOLUME.
CONCLUSIONS: SC to dual reactivity occurs at similar rates in HIV-1 and
HIV-2 women, occurs at higher rates than does SC from HIV-N to HIV-1 or
HIV-2 seropositivity, and tends to be associated with more advanced
immunosuppression. These data suggest that immunosuppressed HIV
seropositive women may be more susceptible to HIV-1 or HIV-2 infection
than are seronegative women and/or that dual reactivity may be a marker
for immunosuppression. Virologic testing will help to investigate these
two possibilities.
DE Cohort Studies Female Human HIV Infections/IMMUNOLOGY *HIV
Seropositivity HIV-1/*IMMUNOLOGY HIV-2/*IMMUNOLOGY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).